SERPINE1 Recombinant Monoclonal Antibody

Code CSB-RA156066A0HU
Size US$210
Order now
  • Western Blot
    Positive WB detected in: U-251 whole cell lysate, U-87 whole cell lysate
    All lanes: PAI1 Antibody at 1:1000
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 46, 44 kDa
    Observed band size: 45 kDa
  • IHC image of CSB-RA156066A0HU diluted at 1:100 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
Plasminogen activator inhibitor 1 (PAI) (PAI-1) (Endothelial plasminogen activator inhibitor) (Serpin E1), SERPINE1, PAI1 PLANH1
Species Reactivity
A synthesized peptide derived from human PAI1
Immunogen Species
Homo sapiens (Human)
Rabbit IgG
Clone No.
Purification Method
It differs from different batches. Please contact us to confirm it.
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:50-1:200
Troubleshooting and FAQs
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

There are four main steps involved in the production of a SERPINE1 recombinant antibody: firstly, sequencing the SERPINE1 monoclonal antibody gene; secondly, cloning the gene into a plasmid vector; thirdly, introducing the recombinant vector into a host cell line; and finally, purifying the SERPINE1 recombinant monoclonal antibody from the cell culture supernatant via affinity chromatography. The SERPINE1 monoclonal antibody is derived from hybridomas that produce the SERPINE1 antibody, with a synthesized peptide from human SERPINE1 used as the immunogen during production. This SERPINE1 recombinant monoclonal antibody is recommended for ELISA, WB, and IHC applications in the detection of human SERPINE1 protein.

The SERPINE1 protein, also known as plasminogen activator inhibitor-1 (PAI-1), is a type of serine protease inhibitor that plays a key role in the regulation of blood clotting and fibrinolysis. SERPINE1 regulates this process by inhibiting the activity of tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), which are responsible for the conversion of plasminogen to plasmin. By inhibiting these enzymes, SERPINE1 effectively blocks the fibrinolytic system and prevents the dissolution of the blood clot. SERPINE1 has also been implicated in a variety of other biological processes, including cell migration, adhesion, and proliferation. Dysregulation of SERPINE1 has been linked to a variety of diseases, including thrombosis, cardiovascular disease, and cancer.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Serine protease inhibitor. Inhibits TMPRSS7. Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots. As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading. Acts as a regulator of cell migration, independently of its role as protease inhibitor. It is required for stimulation of keratinocyte migration during cutaneous injury repair. It is involved in cellular and replicative senescence. Plays a role in alveolar type 2 cells senescence in the lung. Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis.
Gene References into Functions
  1. results of study have not shown that individual genetic variation in PAI-1 is an independent variable that predispose same of children for renal scarring after first febrile urinary tract infection PMID: 29736094
  2. upregulation of PAI-1 may be a critical mechanism underlying insufficient neurotrophic support and increased neurodegeneration associated with AD. Thus, targeting BDNF maturation through pharmacological inhibition of PAI-1 might become a potential treatment for AD. PMID: 28132883
  3. CCL5, from endothelial cells, acts in a paracrine fashion on triple-negative breast cancer (TNBC) cells to enhance their migration, invasion, and metastasis. CCL5, in turn, accelerates TNBC cell secretion of PAI-1 and promotes TNBC cell metastasis, thus forming a positive feedback loop. Moreover, this enhanced metastatic ability is reversible and dependent on CCL5 signaling via the chemokine receptor, CCR5. PMID: 28899878
  4. The present study shows that mean serum TSH and PAI-1 levels were higher in MetS cases as compared to healthy controls and even higher in MetS cases with SCH as compared to MetS cases without SCH. Thus, it can be summarized that in MetS with the presence of thyroid dysfunction, adipocytes behave abnormally and secrete various adipokines such as PAI-1 which in future may lead to thrombotic complication PMID: 29261514
  5. Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling. PMID: 29483508
  6. PAI-1 gene polymorphisms have roles in atherosclerotic diseases [review] PMID: 29908999
  7. Decreased fibrinolytic activity increased, whereas PAI-1 4G/5G polymorphism did not influence venous thrombosis risk in this study. PMID: 28777103
  8. The G-4G-C/A-5G-G PAI-1 haplogenotype may be a genetic marker of susceptibility for obesity and hypertriglyceridemia in Mexican children PMID: 29938477
  9. The analysis of genotype coexistence revealed a higher incidence of the combination of the ACE II and the PAI-1 4G/4G genotypes in the control group (10.0 vs.5.9% in control group; p = 0.17). CONCLUSIONS: The obtained results suggest no apparent association between the ACE I/D, PAI-1 4G/5G polymorphisms and increased RM susceptibility in the analyzed Polish population. PMID: 27321098
  10. Serum PAI-1 level at the time of traumatic brain injury may serve as a predictive biomarker of late pituitary dysfunction in mild traumatic brain injury patients. PMID: 28931364
  11. The personalization of the patients' treatment using uPA/PAI-1 tumor levels allows the reversion of the well-known poor prognostic impact of high uPA/PAI-1 levels and strongly supports the use of this biomarker in clinical practice. PMID: 28685212
  12. Data show that plasminogen activator inhibitor-1 (PAI-1) and chemokine CCL5 (CCL5) overexpression promoted cell proliferation and migration in breast cancer cells. PMID: 29601121
  13. Multiple sclerosis patients were categorized as not cognitively impaired (NCI) and cognitively impaired (CI). The NCI group had a higher percentage of heterozygous subjects but no statistical differences were found between the CI and NCI group. Neuropsychological functioning did not correlate with plasma levels of PAI-1 or its genetic polymorphism. PAI-1 plasma levels were related to neurological impairment. PMID: 29111023
  14. Results demonstrated that EMT could promote the secretion of PAI-1 in the triple negative breast cancer (TNBC) cells. TNBC-secreted PAI-1 could increase cell growth, migration and invasion, and the expression of EMT markers in the TNBC cell lines and xenograft mice model. Most importantly, PAI-1 expression is significantly elevated in the breast cancer tissues and associated with prognosis of patients with TNBC. PMID: 29802992
  15. Plasma PAI-1 levels may be determined by the degree of obesity and triglyceride metabolic disorders. These factors correlate with a decreased LDL-particle size, increasing the risk of atherosclerosis. PMID: 28692480
  16. In this meta-analysis, it was determined that PAI-1 polymorphism confers a genetic contribution to the development of recurrent spontaneous abortion. PMID: 28395596
  17. The A allele and AA genotype of rs6092 in SERPINE 1 may protect against T2 diabetes, and have a protective effect on waist circumference, but a negative effect on Triglycerides in men, while may contribute to a lower HbA1c level in women. PMID: 29627522
  18. Adjuvant chemotherapy was 9% less likely to be recommended by a multidisciplinary board when using the current criteria compared with using a combination of the St. Gallen criteria and Ki67 and uPA/PAI-1 status (P = 0.03). Taken together, our data show discordance among markers in identifying the risk of recurrence, even though each marker may prove to be independently valid. PMID: 28954632
  19. Study shows that hyperglycaemia-induced repression of miR-30c increases PAI-1 expression and thrombus formation in type 2 diabetic mellitus. PMID: 27819307
  20. human plasma protects against endothelial cell apoptosis through sustained BAD phosphorylation, which is achieved by, at least in part, a novel interaction between PP1 with PAI1. PMID: 28296156
  21. Statistically significant association was not found between 4G/4G genotype and CVT risk. PAI-1 4G/4G is a strong risk factor for venous thrombosis in Indian patients and should be included in laboratory testing panel of thrombophil. PMID: 28561456
  22. PAI-1 -675 4G/5G polymorphism was not associated with type 2 diabetes mellitus risk in this population. PMID: 28838342
  23. the association of a gain-of-function polymorphism in the PAI-1 promoter region, rs2227631, with lung function is modified by asthma status. The polymorphism is associated with decreased FEV1/FVC ratio and increased prevalence of airway obstruction in Latino and African American subjects with asthma, but it has no effect in healthy controls. PMID: 28543872
  24. Plasminogen activator inhibitor-1 has a role in determining leukocyte telomere length in American Indians PMID: 28378522
  25. we have identified a detailed molecular mechanism in which p53 acts in partnership with Smad to selectively enhance PAI-1 transcription. PMID: 27759037
  26. PAI-1 is implicated in the pathophysiology of depression. PMID: 27456456
  27. Plasminogen activator inhibitor 1 (PAI-1) is associated with the risk of Alzheimer's disease (AD) in Tunisian patients. PMID: 28466654
  28. PAI-1 levels are increased in patients with recurrent pregnancy losses (RPL), preeclampsia, intrauterine growth restriction (IUGR), gestational diabetes mellitus (GDM) in the previous pregnancy, endometriosis and polycystic ovary syndrome (PCOS). In general, an increased expression of PAI-1 in the blood is associated with an increased risk for infertility and a worse pregnancy outcome. PMID: 28758928
  29. PAI-1/tPA ratio may be an important parameter to monitor the progression of OSMF, and normalizing this ratio to 1:1 may reinstate the normal healing pattern in OSMF cases PMID: 27212010
  30. uPA, uPAR, and PAI-1 expression was up-regulated in the epidermis of psoriatic skin and in tumor cells in basal cell carcinomas. PMID: 28429105
  31. evidence for the significant association of PAI-1 4G/5G polymorphism with an increased risk of adult but not pediatric ischemic stroke (Meta-Analysis) PMID: 26742513
  32. Review/Meta-analysis: indicates a causal effect of elevated PAI-1 level on coronary heart disease risk, which may be mediated by glucose dysfunction. PMID: 28550093
  33. Case Report: mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerization and PAI-1 deficiency. PMID: 28229167
  34. PAI-1 and TGF-beta1 promote non-small cell lung cancer tumor cells and tumor-associated macrophages and might be valuable targets for cancer immunosuppression. PMID: 29253845
  35. This study suggests that PAI-1 is an independent predictor of impaired insulin sensitivity among chronic HIV-infected individuals. PMID: 28322572
  36. Our study suggested that SERPINE1 may be a promising therapeutic target for chemoresistance. PMID: 28975405
  37. PAI-1 mRNA expression is significantly increased in cutaneous lesions of patients with livedoid vasculopathy lesions. PMID: 28186689
  38. We show that the tumor-suppressive actions of MEPs are mediated by PAI-1, uPA and its receptor, uPAR, and are sustained even in the presence of the CAFs, which themselves enhance DCIS tumorigenesis via IL-6 signaling. PMID: 28506312
  39. The concentration of tPA/PAI-1 complex is an independent predictor of mortality from all causes and from cardiovascular causes in patients with heart failure and preserved ejection fraction. PMID: 27975104
  40. tPA:Ag and PAI-1:Ag concentration analysis in diabetic foot syndrome depending on age, gender and BMI did not show any significant differences PMID: 28193577
  41. The homozygous variant 4G/4G also was found to be associated with the higher PAI-1 levels (0.005). The variant allele 4G of PAI-1 4G/5G polymorphism and higher plasma PAI-1 levels were found to be significantly associated with IS in young Asian Indians. PMID: 28460568
  42. uPA/uPAR and SERPINE1 have roles in in head and neck cancer tumor resistance, metastasis, prognosis and therapy [review] PMID: 27385000
  43. High PAI-1 expression is associated radioresistance and aggressiveness of non-small cell lung cancer. PMID: 27004408
  44. The PAI-1 4G/5G genotype was not a relevant predictor of persistent residual venous occlusion after idiopathic deep vein thrombosis, which however was associated with age. PMID: 28347810
  45. data suggest that even an isocaloric exchange of macronutrients - for example, a switch to a fat-rich diet - affects PAI-1 concentrations in humans and that this is highly heritable. PMID: 28633683
  46. The current study revealed a significant increase level of TAFI and PAI-1, coupled with a decrease in PAI-2 in women with severe preeclampsia in comparison with the control group. PMID: 27598010
  47. The abundance of free PAI-1 and TAFI in the plaque may inhibit plasmin generation and thereby counteract plaque destabilization by fibrinolysis, cell migration and inflammation PMID: 28135035
  48. Genotype PAI 4G/4G is significantly more common in patients with allergic rhinitis (28.1% vs. 16.1%; P = 0.017) compared to the genotype 5G/5G. The results suggest that the carriers of at least one 4G allele are at a higher risk for developing symptoms of allergic rhinitis in asthma. PMID: 28258374
  49. Genetic polymorphism in the promoter region of the PAI-1 gene was associated with early onset coronary artery disease. PMID: 27805237
  50. MetS prevalence in the Ghanaian population studied was comparable to that of the industrialized West. PAI-1 may serve as a key link between MetS, as currently defined, and the endpoints with which it is associated. PMID: 27697752

Show More

Hide All

Involvement in disease
Plasminogen activator inhibitor-1 deficiency (PAI-1D)
Subcellular Location
Protein Families
Serpin family
Tissue Specificity
Expressed in endothelial cells. Found in plasma, platelets, and hepatoma and fibrosarcoma cells.
Database Links

HGNC: 8583

OMIM: 173360

KEGG: hsa:5054

STRING: 9606.ENSP00000223095

UniGene: Hs.414795

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To